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Voluntary surveillance systems in Germany suggest 
a recent decline in the incidence of infections (sub-
sequent to at least 2010) with meticillin-resistant 
Staphylococcus aureus (MRSA) from various types of 
specimens and settings. We asked whether this decline 
is reflected by data from the mandatory national sur-
veillance system for invasive MRSA infections. Our 
analysis is based on the population in Germany in 
2010 to 2014. Cases were identified from passive 
reporting by microbiological laboratories of the diag-
nosis of MRSA from blood culture or cerebrospinal 
fluid. Respective clinical data were subsequently 
added to the notification. We calculated risk ratios 
(RR) between consecutive years, stratifying cases by 
sex, age and federal state of residence. The national 
incidence increased from 4.6 episodes per 100,000 
persons in 2010 to 5.6 in 2012 (2011 vs 2010: RR: 1.13, 
95% confidence interval (CI): 1.08–1.18; 2012 vs 2011: 
RR: 1.08, 95% CI: 1.04–1.13). It stagnated at 5.4 per 
100,000 in 2013 (RR: 0.97, 95% CI: 0.93–1.01) before 
declining to 4.8 in 2014 (RR: 0.88, 95% CI: 0.84–0.91). 
This trend was observed in most, but not all federal 
states and strata of sex and age groups. Only 204 of 
20,679 (1%) episodes of infection were notified as 
belonging to an outbreak. Our analysis corroborates 
previous findings that the incidence of invasive MRSA 
infections in Germany may be declining.
Introduction
In 2013, 12.8% (95% confidence interval (CI): 12–14) 
of Staphylococcus aureus isolates from blood culture 
in Germany were found to be resistant to meticillin in 
laboratories submitting data to the European antibi-
otic resistance surveillance network (EARS-Net), plac-
ing Germany below the European average of 18% [1]. 
The prevalence of meticillin-resistant Staphylococcus 
aureus (MRSA) bacteraemia is now within the middle 
lower range of those reported in Europe.
MRSA infections in Germany are thought to be 
mainly healthcare-associated (HA) with only a small 
proportion, which are community-associated or 
livestock-associated [2]. HA-MRSA especially affects 
persons above the age of ca 50 years. Due to unknown 
reasons, the prevalence of HA-MRSA is higher among 
men than women as well as in the northern than south-
ern states of Germany [3,4]. In addition, livestock-asso-
ciated MRSA may account for ca 8% of MRSA isolated 
from blood cultures in regions with a high density of 
swine farming [5].
Analyses from voluntary laboratory- and hospital-
based sentinel surveillance networks for different 
types of specimens and settings suggest a decline in 
the incidence of MRSA infections in Germany, subse-
quent to at least 2010 [1,2,6,7]. These networks are not 
part of the mandatory reporting system and are not 
representative for all of Germany. Many of them, such 
as the EARS-Net, report data solely on the proportion 
of meticillin resistance among all tested S. aureus iso-
lates, which are difficult to translate to incidences. We 
therefore asked whether or not a similar decline could 
be seen in the statutory surveillance system for inva-
sive MRSA infections, which was introduced in 2009 
and allows the direct estimation of incidences [8].
Methods
Study design
We conducted a retrospective cohort study including 
the total of the population in Germany. Cases were 
identified by the mandatory notification system for 
invasive MRSA infections, which was introduced in 
2009. We limited the analysis to the period from 2010 
to 2014, since 2010 was the first year with a full year of 
data collection [8]. As possible confounders or effect 
modifiers we included sex, age and area of cases’ 
residences.
Case notifications
Microbiological laboratories are required to notify 
patients with MRSA positive blood culture or sam-
ples from cerebrospinal fluid (CSF) to the local health 
authorities. Valid tests included in the case definition 
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and reference definition (used for this analysis) are 
culture combined with meticillin sensitivity testing or 
with detection of the MecA gene, e.g. by polymerase 
chain reaction (PCR). The local health authorities sub-
sequently add respective clinical data to these notifi-
cations and transmit them via the state office to the 
national surveillance database, which is maintained 
at the Robert Koch Institute. The German Protection 
against Infection Act mandates transmission to this 
database within two working days after diagnosis. To 
avoid multiple notifications of the same patient, subse-
quent notifications are excluded if reported within two 
weeks [9].
Data on the following case characteristics are transmit-
ted to the Robert Koch Institute: sex, month and year 
of birth, the district of the patient’s home address, the 
place of possible exposure, the date of the notifica-
tion, the date of disease onset, the laboratory methods 
used for diagnosis (type of specimen and test used), 
whether or not the case fulfils the reference definition 
(independently of other variables), clinical symptoms, 
date of death and whether or not the death is due to an 
MRSA-infection, hospitalisation dates, whether or not 
the case is connected to an outbreak. The clinical case 
definition for invasive MRSA infections, as used by 
the German surveillance system, requires the patient 
to have at least one of the following symptoms: fever 
(≥38.5°C), signs of endocarditis, meningitis, menin-
goencephalitis, meningomyelitis, pneumonia or sepsis. 
However, the presence or absence of clinical character-
istics does not change the necessity to notify this case 
to the authorities.
Since August 2011, information on HA infection out-
breaks of epidemiologically-linked nosocomial (symp-
tomatic) infections are additionally transmitted from 
local public health authorities to federal states and 
from there to the Robert Koch Institute [8,10]. In con-
trast to the notification of invasive MRSA infections, 
these notifications include information on the num-
ber of all affected patients; thus cases with non-inva-
sive MRSA infection such as colonised cases are also 
included.
Data of notifications of invasive MRSA infections were 
extracted from the national surveillance database at 
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Year
RD = 0.58 (0.37, 0.80)
RR = 1.13 (1.08, 1.18)
  RD = 0.41 (0.19, 0.64)
RR = 1.08 (1.04, 1.13)
  RD = ‐0.15 (‐0.38, 0.08)
RR = 0.97 (0.93, 1.01)
  RD = ‐ 0.67 (‐0.89, ‐0.45)
RR = 0.88 (0.84, 0.91)
 
MRSA: meticillin-resistant Staphylococcus aureus; RD: risk difference; RR: risk ratio.
The numbers in parentheses indicate 95% confidence intervals. Only notifications marked as fulfilling the reference definition are included.
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the Robert Koch Institute (SurvNet3@RKI) as collected 
up to 1 March 2015.
Population denominator
Aggregated population data in strata of age, sex, 
German federal state and calendar year (31 December 
of the preceding year, i.e. 2009 to 2013) were down-
loaded from the national institute of statistics (www.
destatis.de) on 7 October 2014.
Statistics
We used chi-squared tests to compare categorical 
variables and Kruskal-Wallis tests to compare continu-
ous variables between years. To calculate the annual 
incidence of invasive MRSA infections we categorised 
infections by the year of notification based on the epi-
demiological week number rather than calendar years. 
We then divided their number by the population at risk, 
i.e. the population on 31 December of the preceding 
year. We used chi-squared statistics to calculate confi-
dence intervals around risk differences and risk ratios 
(RR) and to test for differences in incidence between 
years. We classified age in the categories shown based 
on the age distribution of the cases. We chose German 
federal state as the geographic level for analysis since 
a finer break down would have resulted in many empty 
or sparsely populated cells. For the differentiation in 
rural and urban areas we relied on the official German 
categorisation in urban (‘kreisfreie Stadt’) or rural 
districts (‘Landkreis’). Some districts are excluded, 
since they comprised urban areas together with the 
surrounding rural area. For notifications with sev-
eral places of a possible exposure we only included 
one in the analysis, prioritising foreign countries over 
Germany and other German states over those that 
equalled the notifying state. Since earlier software 
Figure 2
Incidence of notified episodes of invasive meticillin-resistant Staphylococcus aureus infections per 100,000 persons stratified 






























M: men; w: women; y: years-old.
The asterisk marks significant differences (p < 0.05) between 2012 and 2014. Only notifications marked as fulfilling the reference definition are 
included.
a 12 cases of 20,679 were excluded due to missing data for sex or age.
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products automatically set the place of exposure to the 
notifying state, the answer ‘unknown’ and ‘same state 
as notification’ were grouped together as one category. 
To assess the presence of effect modification we used 
the Mantel-Haenszel test for homogeneity. Throughout 
the analysis, tests were considered significant if the 
p-value was below 0.05. 
We analysed the data with Stata SE13 (College Station, 
Texas, US). Maps were produced by Regiograph Planing 
Version 13 (GFK GeoMarketing GmbH, Germany).
Reporting
We followed the recommendations given in the 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement [11].
Ethics
The study was based on the statutory case notifica-
tions as mandated by the German Protection against 
Infection Act. These data were available in anonymised 
form at national level. Ethical approval for analysis of 
such surveillance data are not required according to the 
Medical Association’s professional code of conduct.
Results
Case characteristics
Between 2010 and 2014 there were 20,764 notifica-
tions of invasive MRSA infections in Germany. Eighty-
five (0.4%) of them were excluded, since the reference 
definition was not fulfilled, resulting in a final study 
population of 20,679 notifications.
The characteristics of the included cases by year of 
notification are shown in Table 1 and 2. While the age 
distribution of the notified cases remained remark-
ably stable over the years, there were a number of 
other small but statistically significant changes. These 
include changes in the distribution of cases between 
the sexes, the German federal states, rural and urban 
areas, the type of specimen used for diagnosis, the 
proportion fulfilling the clinical case definition, sev-
eral clinical symptoms, the proportion hospitalised, 
those with dates on disease onset and hospitalisation, 
those with a hospital onset of the infection, the mortal-
ity and case fatality ratios. Notable is an increase in 
the proportion and absolute numbers of patients with 
clinical signs of sepsis between 2010 and 2013, as well 
as those with sepsis due to a central vein catheter or 
other invasive access. The absolute numbers in both 
categories of cases however declined again in 2014 as 
compared with 2013.
Only few notifications of invasive MRSA infections 
were marked as being associated with a nosocomial 
outbreak (such notifications are independent of the 
transmission of data on nosocomial outbreaks as 
introduced in 2011). These amounted to a total of 204 
of 20,679 (1%) for the whole study period, 37 of 3,754 
(1%) for 2010, 37 of 4,227 (1%) for 2011, 31 of 4,485 
(1%) for 2012, 40 of 4,372 (1%) for 2013, and 59 of 3,841 
(2%) for 2014 (p = 0.002).
Remarkably, in patients with known disease onset and 
hospitalisation dates, few episodes (39%) of illnesses 
due to invasive MRSA occurred while patients were 
within the hospital. HA-MRSA infection was defined as 
disease onset later than the second day of hospitalisa-
tion but before or on the day of discharge.
The case fatality rate was 8%, with small but significant 
variations between the years. The cases with known 
dates of death and disease onset appeared to have a 
relatively short time between illness onset and death, 
with a median of seven days (interquartile range: 3 to 
18). This short period can be explained by an underre-
porting of later deaths due to an undefined time point 
for follow-up by the public health department.
Possibility of recurrent infections
Even though unique personal identifiers are not 
included in the final dataset, we tried to assess the 
frequency of persons with repeated episodes of MRSA 
infections per year. We analysed the dataset for repeti-
tions of the same combination of birth month and year, 
sex, district and notification year in the dataset. Over 
all five years (n=20,679 cases), we found 490 (2%) of 
these repetitions per year, suggesting that more than 
one episode of invasive MRSA infection in the same 
patient was rare. Of note, 71 (14%) of the repeated noti-
fications were within two weeks of a previous notifi-
cation, allowing for the possibility of double entries of 
the same episode.
Trends in the incidence of invasive meticillin-
resistant Staphylococcus aureus infections
The incidence of invasive MRSA infections in Germany 
increased from 4.6 episodes per 100,000 persons in 
2010 to 5.6 per 100,000 persons in 2012. With 5.4 epi-
sodes per 100,000 persons, it remained high in 2013, 
before dropping to 4.8 episodes per 100,000 persons in 
2014. The risk difference and risk ratios (RR) between 
consecutive years are significant, with the exception 
of the years 2012 and 2013 (Figure 1). Results did not 
change appreciably when including all notified cases 
regardless of reference definition or when restricted 
to those specifying the origin of the sample as either 
blood or CSF (data not shown).
The effect of age, sex, state, and urban vs rural 
areas
The incidence is increasing with age, starting at ca 50 
years of age (Figure 2). It was nearly double among men 
compared with women (RR: 1.79, 95% CI: 1.74–1.85), 
with the exception of children and adults below 50 
years of age. It differed by a factor of ca four between 
federal states, with generally higher incidences in 
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The asterisk marks significant differences (p < 0.05) between 2012 and 2014. Only notifications marked as fulfilling the reference definition are 
included.
a Five cases of 20,679 were excluded due to missing data.
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A decline in the MRSA incidence between 2012 and 
2014 is found for most but not all strata of age, sex, 
and state, as well as for rural and urban areas (Figure 2 
to 4). For example the decrease in incidence from 2013 
to 2014 is seen in all strata of age and sex, except for 
women between 1 to 50 years of age (test for homo-
geneity: p = 0.01). Similarly, some states had even an 
increase in incidence in 2014 (Brandenburg, Bremen, 
Lower Saxony, Thuringia) or in 2013 (Brandenburg, 
Berlin, Hamburg, Lower Saxony, Mecklenburg-West 
Pomerania, Saxony-Anhalt) as compared with the pre-
ceding year (test for homogeneity for 2014 vs 2013: 
p = 0.005; for 2013 vs 2012: p = 0.003). These differ-
ences are not due to confounding since the age struc-
ture in Germany remained relatively stable during the 
time of the analysis and since the stratified and crude 
Mantel-Haenszel estimates were similar.
Outbreaks
As part of the notification for HA outbreaks, which are 
independent of the notification of invasive MRSA infec-
tions, a total of 95 outbreaks of MRSA were reported 
for the years 2012 to 2014. These comprise colonisa-
tion and all types of MRSA-infections, not only invasive 
infections. In 2012 there were 27 outbreaks compris-
ing 120 cases (among those 98 infected, 20 colonised 
und 2 unspecified), 30 outbreaks with 143 cases (71 
infected, 54 colonised and 18 unspecified) in 2013 and 
38 outbreaks with 209 cases (79 infected, 103 colo-
nised and 27 unspecified) in 2014.
Discussion
This is the first trend analysis of the incidence of inva-
sive MRSA infections including the complete population 
in Germany. We found that the annual incidence of 
notified invasive MRSA infections increased from 2010 
until its peak in 2012 to 2013 before declining again in 
2014. We additionally observed statistically different 
trends between German federal states and to a lesser 
extent between some categories of age and sex, sug-
gesting different trends at local level and possibly for 
certain patient groups.
As with all passive surveillance systems, underreport-
ing and effects due to changes in the reporting com-
pliance cannot be excluded. Especially during the first 
years after the inclusion of MRSA in the national sur-
veillance system underreporting and the number of 
data errors may have been high due to a lack of train-
ing and due to technical problems [12]. We therefore 
think that the increase in 2011, and possibly in 2012 
may in part be due to a surveillance artefact and it may 
also explain changes in clinical symptoms, such as the 
increase of clinical sepsis. However, given an assumed 
stabilisation of the surveillance system we believe that 
the decline in 2014, even though small, is likely to be 
real. The decline in 2014 includes cases with clinical 
sepsis as well as those with sepsis and central vein 
catheter or other invasive access, which further cor-
roborates this interpretation.
Germany has done much to control its MRSA epidemic. 
This includes the implementation of a national anti-
biotic resistance strategy (DART, 2008 updated 2015) 
(www.bmg.bund.de), the establishment of regional 
networks to combat multiresistant bacteria (since 2004 
with the support of the Robert Koch Institute) [13], the 
conduction of various screening programmes [14-16], 
the adaption of respective clinical guidelines (http://
www.awmf.org), the development of antibiotic stew-
ardship programmes, additional legislation on federal 
state levels, recommendations by the Robert Koch 
Institute concerning hospital hygiene (www.rki.de) and 
the establishment of various surveillance systems such 
as the mandatory reporting for invasive MRSA infec-
tions in 2009 and the antibiotic resistance surveillance 
(ARS) in 2007 [7]. It is therefore tempting to think that 
these interventions had some effect on the incidence 
of invasive MRSA infections. However, surveillance 
data are rarely suitable to prove causal links. We can-
not exclude other causes, such as changes in the fre-
quency of testing and biological mechanisms [17]. For 
example with additional testing, which is likely to have 
occurred due to an increased awareness of the possi-
bility of antibiotic resistance, the number of detected 
and reported cases is likely to increase [18]. A bio-
logical factor possibly contributing to the decrease of 
MRSA in Germany is the reduction of epidemic clones 
throughout central Europe [19], as well as shifts of epi-
demic strains found within Germany [20].
The decline in the incidence of invasive MRSA infec-
tions reported here is smaller and occurred later than 
that suggested by other German surveillance systems. 
For example, in the laboratory-based ARS network the 
Figure 4
Incidence of notified episodes of invasive meticillin-
resistant Staphylococcus aureus infections per 100,000 
persons according to year of notification and urban or 





























The asterisk marks significant differences (p < 0.05) between 2012 
and 2014. Only notifications marked as fulfilling the reference 
definition are included.
a 644 cases of 20,679 could not be attributed to either rural or 
urban areas.
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percentage of oxacillin resistance in blood culture col-
lected from inpatients declined from a peak of 24% 
(95% CI: 22.5–27.0) in 2010 to 18.4% (95% CI: 16.5–
20.3) in 2011 [7] and is currently at 13% (www.ars.rki.
de). The EARS-net reported a decline in the proportion 
of MRSA among S. aureus isolates for Germany from 
20.9% in 2010 to 12.8% in 2013 [1], the triennial sur-
vey by the Paul Ehrlich Institute found a decline from 
30.3% in 2007 to 16.7% in 2010 [21] and data from the 
hospital infections surveillance system (KISS) suggest 
a decline from 33% in 2007 to 27% in 2012 among 
nosocomial S. aureus infections [6]. This may in part 
be explained by the different indicators used and the 
possible non-representativeness of these voluntary 
systems, but more probably is due to the underreport-
ing in the national reporting system in the first years. 
Thus a definite conclusion concerning the start of the 
decline cannot be made.
Despite the decrease in 2014, the incidence of 4.8 
invasive MRSA infections per 100,000 persons in 
Germany is still higher than that in some neighbouring 
countries, such as Denmark (1 case of MRSA bacterae-
mia per 100,000 in 2014) [22], western Sweden (one 
case of community onset MRSA blood stream infection 
between 2004 and 2008 for a catchment population of 
256,000) [23] and England, where, after intensification 
of control mechanisms, a recent decline was reported 
Characteristics Total 2010 2011 2012 2013 2014 P-value 
N 20,679 3,754 4,227 4,485 4,372 3,841 –
Female n (%) 7,595 (37) 1,392 (37) 1,573 (37) 1,608 (36) 1,668 (38) 1,354 (35) 0.05
Median age in years (IQR) 74 (64, 80) 73 (65, 80) 73 (64, 80) 73 (64, 80) 74 (64, 80) 74 (64, 80) 0.47
Age group in years, n (%)
  < 1 67 (0) 10 (0) 14 (0) 12 (0) 22 (1) 9 (0)
0.23
  1 to 49 1,392 (7) 245 (7) 285 (7) 304 (7) 279 (6) 279 (7)
  50 to 59 2,159 (10) 400 (11) 458 (11) 485 (11) 445 (10) 371 (10)
  60 to 69 3,877 (19) 731 (19) 788 (19) 803 (18) 809 (19) 748 (19)
  70 to 79 7,508 (36) 1,321 (35) 1,554 (37) 1,641 (37) 1,569 (36) 1,423 (37)
  ≥80 5,673 (27) 1,047 (28) 1,127 (27) 1,242 (28) 1,247 (29) 1,010 (26)
Federal state of residence, n (%)
  Baden-Württemberg 1,234 (6) 292 (8) 248 (6) 253 (6) 255 (6) 186 (5)
< 0.001
  Bavaria 1,730 (8) 378 (10) 385 (9) 358 (8) 356 (8) 253 (7)
  Berlin 1,486 (7) 285 (8) 304 (7) 306 (7) 321 (7) 270 (7)
  Brandenburg 772 (4) 152 (4) 173 (4) 139 (3) 153 (4) 155 (4)
  Bremen 101 (0) 22 (1) 22 (1) 24 (1) 15 (0) 18 (0)
  Hamburg 214 (1) 0 (0) 57 (1) 26 (1) 67 (2) 64 (2)
  Hesse 1,274 (6) 302 (8) 266 (6) 271 (6) 257 (6) 178 (5)
  Mecklenburg-West Pomerania 653 (3) 97 (3) 134 (3) 143 (3) 145 (3) 134 (3)
  Lower Saxony 2,655 (13) 514 (14) 571 (14) 498 (11) 531 (12) 541 (14)
  North Rhine-Westphalia 6,123 (30) 944 (25) 1,160 (27) 1,457 (33) 1,354 (31) 1,208 (31)
  Rhineland-Palatinate 664 (3) 154 (4) 153 (4) 156 (3) 110 (3) 91 (2)
  Saarland 189 (1) 0 (0) 28 (1) 58 (1) 54 (1) 49 (1)
  Saxony 1,359 (7) 202 (5) 290 (7) 296 (7) 295 (7) 276 (7)
  Saxony-Anhalt 849 (4) 157 (4) 164 (4) 179 (4) 182 (4) 167 (4)
  Schleswig-Holstein 824 (4) 144 (4) 153 (4) 213 (5) 177 (4) 137 (4)
  Thuringia 547 (3) 111 (3) 119 (3) 105 (2) 98 (2) 114 (3)
Type of area, n (%)
  Rural 12,649 (61) 2,278 (61) 2,596 (61) 2,715 (61) 2,723 (62) 2,337 (61)
< 0.001  Urban 7,386 (36) 1,310 (35) 1,506 (36) 1,604 (36) 1,560 (36) 1,406 (37)
  Undefined 644 (3) 166 (4) 125 (3) 166 (4) 89 (2) 98 (3)
Place of possible exposure, n (%)
  Other federal state than state of notification 275 (1) 39 (1) 55 (1) 64 (1) 55 (1) 62 (2) 0.26
  Outside of Germany 40 (0) 4 (0) 5 (0) 11 (0) 10 (0) 10 (0) 0.34
IQR: interquartile range.
Only notifications marked as fulfilling the reference definition are included. Missing data were less than 0.1%, except for the exposure place, 
where the exact number could not be identified due to technical reasons. 
Table 1
Demographic characteristics of patients with invasive meticillin-resistant Staphylococcus aureus infection in Germany by 
year of notification, 2010–2014 (n=20,679)
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Characteristics Total 2010 2011 2012 2013 2014 P-value 
N 20,679 3,754 4,227 4,485 4,372 3,841 –
Type of specimen for diagnosis, n (%)
Blood 19,318 (93) 3,587 (96) 3,837 (91) 4,156 (93) 4,126 (94) 3,612 (94)
< 0.001
CSF 117 (1) 24 (0) 13 (0) 37 (1) 25 (1) 18 (0)
CSF and blood 17 (0) 2 (0) 5 (0) 1 (0) 3 (0) 6 (0)
Not indicated 1,227 (6) 141 (4) 372 (9) 291 (6) 218 (5) 205 (5)
Clinical case definition fulfilled, n (%)
Yes 18,775 (91) 3,343 (89) 3,855 (91) 4,133 (92) 3,967 (91) 3,477 (91)
< 0.001No 1,245 (6) 195 (5) 308 (7) 260 (6) 302 (7) 180 (5)
Unknown 659 (3) 216 (6) 64 (2) 92 (2) 103 (2) 184 (5)
Patients with available data on clinical symptoms, n (%)
With data 18,268 (88) 3,329 (89) 3,609 (85) 3,978 (89) 3,890 (89) 3,462 (90) < 0.001
Clinical symptoms among those with available data (N=18,268), n (%)a
  Fever 13,697 (75) 2,444 (73) 2,739 (76) 3,036 (76) 2,876 (74) 2,602 (75) 0.02
  Signs of meningitis, meningoencephalitis or 
meningomyelitis 1,813 (10) 44 (1) 493 (14) 494 (12) 457 (12) 325 (9) < 0.001
  Pneumonia 3,494 (19) 588 (18) 681 (19) 778 (20) 760 (20) 687 (20) 0.15
  Endocarditis 428 (2) 67 (2) 79 (2) 99 (2) 89 (2) 94 (3) 0.35
  Lesion, skin abscess or ulcer 269 (1) 0 (0) 0 (0) 1 (0) 68 (2) 200 (6) < 0.001
  Screening examination 304 (2) 0 (0) 0 (0) 0 (0) 64 (2) 240 (7) < 0.001
  Sepsis 12,086 (66) 1,682 (51) 1,866 (52) 2,678 (67) 3,135 (81) 2,725 (79) < 0.001
Characteristics among patients with sepsis (N=12,086), n (%)a
    Central vein catheter or other invasive 
access 4,324 (36) 511 (30) 675 (36) 979 (37) 1,105 (35) 1,054 (39) < 0.001
    Other foreign object associated infection 594 (5) 50 (3) 69 (4) 124 (5) 190 (6) 161 (6) < 0.001
    MRSA infection of known focus 5,425 (45) 12 (1) 622 (33) 1,298 (48) 1,846 (59) 1,647 (58) < 0.001
Characteristics among MRSA infections of known focus (N=5,425), n (%)a
      Urinary tract 1,031 (19) 5 (42) 124 (20) 226 (17) 358 (19) 318 (19) 0.15
      Abdomen (e.g. after operation) 267 (5) 1 (8) 35 (6) 75 (6) 90 (5) 66 (4) 0.20
      Respiratory tract 1,777 (33) 1 (8) 208 (33) 438 (34) 587 (32) 534 (33) 0.31
      Skin or soft tissue 2,291 (42) 4 (33) 265 (43) 576 (44) 781 (42) 665 (40) 0.27
      Bones or joints 399 (7) 0 (0) 41 (7) 82 (6) 150 (8) 126 (8) 0.25
      Other 596 (11) 2 (17) 67 (11) 140 (11) 217 (12) 170 (10) 0.67
Hospitalisation, n (%)
Yes 18,423 (89) 3,281 (87) 3,753 (89) 4,065 (91) 3,897 (89) 3,427 (89)
< 0.001No 1,675 (8) 437 (12) 417 (10) 357 (8) 315 (7) 149 (4)
Unknown 581 (3) 36 (1) 57 (1) 63 (1) 160 (4) 265(7)
Date of onset of symptoms and of 
hospitalisation known, n (%) 11,273 (55) 1,774 (47) 2,163 (51) 2,490 (56) 2,510 (57) 2,336 (61) < 0.001
  Among these, symptom onset while in 
hospital n (%)b 4,412 (39) 646 (36) 818 (38) 993 (40) 1,036 (41) 928 (40) 0.01
Vital status
Vital status known n (%) 20,293 (98) 3,694 (98) 4,151 (98) 4,433 (99) 4,353 (100) 3,662 (95) < 0.001
Mortality among those with vital status known (N=20,293)
  All-cause mortality n (%) 1,973 (10) 320 (9) 366 (9) 437 (10) 396 (9) 454 (12) < 0.001
  Case fatality rate n (%)c 1,580 (8) 319 (9) 354 (9) 359 (8) 293 (7) 255 (7) < 0.001
Time from symptom onset to death, median 
days (IQR)d 7 (3, 18) 9 (3, 20) 6 (3, 18) 8 (4, 21) 7 (3, 17) 6 (2, 15) 0.04
CSF: cerebrospinal fluid; IQR: interquartile range; MRSA: meticillin-resistant Staphylococcus aureus. 
Only notifications marked as fulfilling the reference definition are included. Missing data were less than 1% or are as indicated. 
a Several categories could apply simultaneously. Thus the total may tally to more than 100%.
b Onset > 2 days after hospitalisation and before or on discharge.
c MRSA infection identified as a cause of death.
d Based on patients with available data: n=187 in 2010, 252 in 2011, 295 in 2012, 289 in 2013, 335 in 2014.
Table 2
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in 2014 (with an incidence of 1.6 case of MRSA bacte-
raemia per 100,000 in that year) [24]. This indicates 
that still more needs to be done in Germany as well. 
Finally, a decline in invasive MRSA infections does not 
necessarily mean that other forms, such as livestock-
associated and community-associated MRSA infec-
tions, are also declining. These forms are not properly 
captured by the surveillance system analysed here. 
However, data from the voluntary ARS system indicate 
declines in various forms of MRSA infections (https://
ars.rki.de/).
A possible focus for further interventions should 
include the MRSA management in ambulatory settings 
and a more rigorous detection of outbreaks. Similar to 
data from various other countries [23,25], 61% of the 
patients with available hospitalisation and disease 
onset dates, had an onset before day three of hospi-
talisation, indicating that colonisation and infections 
may occur before hospitalisation possibly in the com-
munity. Furthermore, only 1% of cases were associated 
with outbreaks. While it is unclear, which proportion 
of MRSA infections is expected to be caused by out-
breaks, we think that the notified number is a large 
underestimation, especially given the fact that only 
invasive infections are to be notified and detection of 
MRSA at other body sites is much more frequent. The 
increase in the number of reported outbreaks from 27 
in 2012 to 38 in 2014 with a simultaneous decrease of 
the number of infected persons and an increase of col-
onised persons is however a promising sign, that more 
outbreaks are being detected and reported.
The mortality and case fatality rate of respectively 10% 
and 8% observed in this study were lower than those 
reported in the literature [26-28]. For example one 
study reported a case fatality rate of 22% for commu-
nity-onset MRSA bacteraemia [28] and a multicentre 
prospective study in 13 European hospitals found a 
mortality for MRSA bloodstream infection of 36% [26]. 
We believe this to be due to the lack of a defined follow-
up period in the German surveillance system. There are 
no strict rules for when the public health department 
should collect patient information including the treat-
ment outcome. Therefore, the values presented here 
are likely to be underestimations.
The causes for the higher incidence among men are not 
clear, even though previously shown by other surveil-
lance systems in Germany [4] and elsewhere [24]. In 
our data a difference according to sex becomes only 
apparent among older patients suggesting medical or 
behavioural factors in this age group as the key driver. 
More studies are however needed to better understand 
the underlying causes for this association. Similarly, 
studies are needed to investigate the causes for the 
higher incidence in the north of Germany.
The study has further limitations in addition to those 
already mentioned above. These include the absence 
of federal validation processes of the notification 
system, since communicable disease management is 
in the responsibility of the German federal states. A 
limitation is also the notification by patients’ home 
addresses, which may not be the place of exposure. 
This may especially lead to an underestimation of the 
incidence in urban areas, if many patients from sur-
rounding districts are treated in a nearby urban cen-
tre, but are notified for their home address. Finally, the 
number of software packages and versions available 
for the local public health office may result in different 
implementation of some variables, such as the clinical 
symptoms, which are difficult to understand retrospec-
tively at the national level. Thus trends over time in 
some variables may be biased due to delayed updates 
of software or changes in the proportion of various 
software packages over time. Finally, the absence of a 
personal identifier does not allow identifying recurrent 
infections with certainty.
In summary, data from the national surveillance sys-
tem corroborate previous reports that the incidence 
of MRSA infections in Germany may be declining. 
However, additional studies are needed to better 
understand its causes and to accelerate this still mod-
est downward trend.
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